GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vexicitinib   Click here for help

GtoPdb Ligand ID: 14367

Synonyms: compound I [WO2022188796]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Vexicitinib is one of the INNs included in WHO proposed list 134 (Feb 2026). It is proposed as a Janus kinase inhibitor, for anti-inflammatory/immunosuppressant activities. The compound is claimed in patent WO2022188796A1 [2]. Interrogation of online sources suggests that vexicitinib is likely the INN for clinical candidate SYHX1901, which is an orally bioavailable dual JAK-Syk inhibitor [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 150.1
Molecular weight 499.59
XLogP -0.2
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1CC1NC2=C(C=NC(=N2)NC3=CC=C4C(=C3)OC[C@@]5([H])CN(CCN54)CS(=O)(=O)C6CC6)C(=O)N
Isomeric SMILES [H][C@@]12COC3=C(C=CC(NC4=NC=C(C(N)=O)C(NC5CC5)=N4)=C3)N1CCN(CS(=O)(=O)C6CC6)C2
InChI InChI=1S/C23H29N7O4S/c24-21(31)18-10-25-23(28-22(18)26-14-1-2-14)27-15-3-6-19-20(9-15)34-12-16-11-29(7-8-30(16)19)13-35(32,33)17-4-5-17/h3,6,9-10,14,16-17H,1-2,4-5,7-8,11-13H2,(H2,24,31)(H2,25,26,27,28)/t16-/m1/s1
InChI Key UUNAWUCGRQGIAD-MRXNPFEDSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
SYHX1901 was progressed as a clinical candidate for autoimmune inflammatory diseases, primarily plaque psoriasis. Efficacy in a phase 2 human trial has been reported [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06943950 A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis Phase 3 Interventional CSPC Ouyi Pharmaceutical Co., Ltd.
NCT06562894 Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients Phase 2 Interventional CSPC Ouyi Pharmaceutical Co., Ltd.
NCT06511739 A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients Phase 2 Interventional CSPC Ouyi Pharmaceutical Co., Ltd.
NCT05858047 An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis Phase 2 Interventional CSPC Ouyi Pharmaceutical Co., Ltd.